---
title: "新天地药业股份有限公司 (301277.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301277.SZ.md"
symbol: "301277.SZ"
name: "新天地药业股份有限公司"
industry: "制药"
---

# 新天地药业股份有限公司 (301277.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.newlandpharma.com](https://www.newlandpharma.com) |

## Company Profile

公司成立于 2005 年。是全球重要的阿莫西林合成侧链——左旋对羟基苯甘氨酸生产企业，牵头或参与制定了左旋对羟基苯甘氨酸、对甲苯磺酸及左旋对羟基苯甘氨酸甲酯等多个产品的行业标准，是河南省第二批专精特新企业。公司业务主要分为医药中间体业务、原料药业务以及制剂业务。公司主要产品为左旋对羟基苯甘氨酸系列产品、对甲苯磺酸系列产品、括盐酸利多卡因、盐酸萘甲唑啉、维格列汀、盐酸莫西沙星、艾司奥美拉唑镁、他达拉非等，覆盖抗感染、糖尿病、局部麻醉等。公司获得许昌市 “无废工厂”、河南省绿色发展协会 “无废企业” 荣誉。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:10.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 146 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.03% |  |
| Net Profit YoY | -24.61% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.21 |  |
| Dividend Ratio | 2.29% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.89B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 670.44M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.16% | B |
| Profit Margin | 18.45% | A |
| Gross Margin | 31.40% | C |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.03% | D |
| Net Profit YoY | -24.61% | D |
| Total Assets YoY | 0.25% | C |
| Net Assets YoY | 0.69% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 541.90% | C |
| OCF YoY | -4.03% | D |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.38 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 12.74% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 新天地药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.16%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "18.45%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "31.40%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-4.03%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.61%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.25%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.69%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "541.90%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-4.03%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "12.74%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 39.52 | 93/222 | 40.18 | 36.76 | 28.12 |
| PB | 3.21 | 140/222 | 3.64 | 3.33 | 3.04 |
| PS (TTM) | 7.29 | 155/222 | 7.84 | 7.36 | 6.56 |
| Dividend Yield | 2.29% | 45/222 | 2.30% | 2.14% | 1.88% |

## References

- [Company Overview](https://longbridge.com/en/quote/301277.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301277.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301277.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.